Coherus Biosciences | CHRS

Stock Price
1.67
Daily Change
-0.02 -1.18%
Monthly
-24.61%
Yearly
50.45%
Q1 Forecast
1.58



Peers Price Chg Day Year Date
Fujifilm 3,244.00 55.00 1.72% 7.13% Feb/27
AbbVie 232.08 7.39 3.29% 11.03% Feb/27
Acadia Pharmaceuticals 24.56 -0.08 -0.32% 25.31% Feb/27
Akebia Therapeutics 1.31 -0.01 -0.76% -29.19% Feb/27
ALKERMES 30.23 -0.50 -1.63% -11.94% Feb/27
Alnylam Pharmaceuticals 332.92 1.68 0.51% 34.92% Feb/27
Amgen 388.16 8.83 2.33% 26.00% Feb/27
Amarin 13.98 -0.15 -1.03% 28.94% Feb/27
Baxter International 20.37 0.01 0.05% -40.97% Feb/27
Biogen 191.79 3.77 2.01% 36.51% Feb/27

Indexes Price Day Year Date
USND 22668 -210.17 -0.92% 20.27% Feb/27
US400 3575 -29.16 -0.81% 15.51% Feb/27

Coherus Biosciences traded at $1.67 this Friday February 27th, decreasing $0.02 or 1.18 percent since the previous trading session. Looking back, over the last four weeks, Coherus Biosciences lost 24.61 percent. Over the last 12 months, its price rose by 50.45 percent. Looking ahead, we forecast Coherus Biosciences to be priced at 1.58 by the end of this quarter and at 1.44 in one year, according to Trading Economics global macro models projections and analysts expectations.

Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.